Evidence map›Paper›PMID 40172631›Full record

ReviewDie Anaesthesiologie2025

[Point of care coagulation diagnostics-Absolutely necessary or only a reasonable supplement?]

Martin Mirus, Herbert Schöchl, Philipp Groene, Mirjam Bachler, Jürgen Koscielny, Dietmar Fries, Lars Heubner

Abstract readEnglish AbstractReview
PubMed Publisher
In one paragraph

Review in Die Anaesthesiologie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Review
  3. Observational
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Martin MirusKlinik und Poliklinik für Anästhesiologie und Intensivtherapie, Medizinische Fakultät und Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Fetscherstraße 74, 01307, Dresden, Deutschland.
Herbert SchöchlLudwig Boltzmann Institut Traumatologie Das Forschungszentrum in Kooperation mit der AUVA, Donaueschingenstr. 13, Wien, Österreich.
Philipp GroeneKlinik für Anästhesiologie, Universitätsklinikum LMU München, München, Deutschland.
Mirjam BachlerUniversitätsklinik für Anästhesiologie und Intensivmedizin, Medizinische Universität Innsbruck, Innsbruck, Österreich.
Jürgen KoscielnyGerinnungsambulanz mit Hämophiliezentrum, Charité, Universitätsmedizin Berlin, Berlin, Deutschland.
Dietmar FriesUniversitätsklinik für Anästhesiologie und Intensivmedizin, Medizinische Universität Innsbruck, Innsbruck, Österreich.
Lars HeubnerKlinik und Poliklinik für Anästhesiologie und Intensivtherapie, Medizinische Fakultät und Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Fetscherstraße 74, 01307, Dresden, Deutschland. lars.heubner@uniklinikum-dresden.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Point of care (POC) coagulation diagnostics have become an integral part of clinical patient care. In particular, the strengths of POC viscoelastometry (VET) lie not only in the rapid availability of test results but also in the fact that VET provides insights into coagulation that cannot be detected by standard laboratory tests. The relevance of POC-VET in the optimal management of patients with acutely acquired bleeding disorders, such as trauma-induced coagulopathy, is now unquestioned and is also reflected in the corresponding guidelines; however, VET also provides important information about fibrinolysis and fibrinolytic activity and in combination with other laboratory values can possibly also be sensitive for prothrombotic coagulation disorders. Therefore, POC-VET is increasingly being used in intensive care medicine. The use of POC diagnostics is not subject to the same standards as central laboratory testing. In order to maintain high quality and avoid harming patients, the requirements for medical device manufacturers in particular have been increased as part of the in vitro diagnostic reagents (IVDR) regulations, which places high demands on quality management in particular. The variety of POC devices and the lack of comparability between them remains an unsolved problem. It should be critically discussed to what extent medical device manufacturers and pharmaceutical companies could be legally required to keep unique and urgently needed technologies on the market, especially if no comparable alternatives will be available in the foreseeable future. Overall, from today's perspective, the use of POC coagulation diagnostics is essential for optimal patient care.

Indexed as

Blood Coagulation DisordersPoint-of-Care SystemsPoint-of-Care TestingBlood Coagulation TestsHumansThrombelastographyBleedingCoagulopathyDiagnosticsThrombosisViscoelastometry

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.